<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667678</url>
  </required_header>
  <id_info>
    <org_study_id>1508032</org_study_id>
    <secondary_id>2015-001455-68</secondary_id>
    <nct_id>NCT02667678</nct_id>
  </id_info>
  <brief_title>5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients</brief_title>
  <acronym>HIVOL2</acronym>
  <official_title>5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the biomarkers levels as IL-18, KIM-1 and Cystatin C for
      patients infected by HIV with failure in renal function at year 5. The main criterion will be
      a degradation of the glomerular filtration throughput measured. It will be compared to
      clinical scores of degradation risks of renal function for patients infected with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the biomarkers levels as IL-18, KIM-1 and Cystatin C for
      patients infected by HIV with failure in renal function at year 5. The main criterion will be
      a degradation of the glomerular filtration throughput measured. It will be compared to
      clinical scores of degradation risks of renal function for patients infected with HIV.

      From 2011 to 2013, researchers realized a study called HIVOL, on the diagnostic performance
      of GFR (Glomerular Filtration Rate) estimators in patients infected with HIV. It lead to a
      publication in AIDS, retaken in the rational of recommendations of Infectious Diseases
      Society of America for the Chronic Renal Diseases support for patients infected with HIV.

      235 patients were involved, for everyone researchers have a GFR measure (by Iohexol plasmatic
      clearance) and urinary and plasma samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage of chronic kidney disease (according to the Glomerular Filtration Rate)</measure>
    <time_frame>Day 1</time_frame>
    <description>The aim of this study is to compare the level of biological biomarkers as microalbuminuria, proteinuria, KIM-1, IL-18, and Cystatin C with the level of this markers 5 years ago, for the HIVOL study performed between 2011 and 2013. These levels will allow the researchers to have an idea concerning the renal function of the patients followed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort HIVOL, patients infected by HIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cohort HIVOL, patients infected by HIV</intervention_name>
    <description>Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.</description>
    <arm_group_label>Cohort HIVOL, patients infected by HIV</arm_group_label>
    <other_name>Blood and urinary samples</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affiliated or entitled to a social security scheme

          -  Patient HIV infected

          -  Patient included in the HIVOL cohort with a GFR measure available

          -  Patients who have given their consent in writing

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients treated with metformin

          -  Patients with a known allergy, regardless the type of allergy

          -  Patients with a history of thyroid dysfunction

          -  Any biological anomaly in the selection, which in the opinion of the investigator, may
             indicate a contraindication to the patient's participation in this study

          -  Degradation recent (not older than three months) of renal function defined as the
             degradation of more than 25 % GFR.

          -  Estimated GFR of less than 15 mL / min / 1.73m2

          -  History of major immediate or delayed skin reaction known to the injection of
             iodinated contrast medium (OMNIPAQUE®)

          -  Manifest thyrotoxicosis

          -  Hypersensitivity to the active substance or to any of the excipients (OMNIPAQUE®)

          -  Patient who expressed his refusal to participate in the study

          -  Patient justice under protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAGNEUX-BRUNON Amandine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GAGNEUX-BRUNON Amandine, MD</last_name>
    <email>amandine.gagneux-brunon@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LABRUYERE Carine, CRA</last_name>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAGNEUX-BRUNON Amandine, MD</last_name>
      <email>amandine.gagneux-brunon@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>GAGNEUX-BRUNON Amandine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>LUCHT Frédéric, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BOTELHO-NEVERS Elisabeth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FRESARD Anne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAZORLA Céline, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUGLIELMINOTTI Claire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>DAOUD Fatiha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

